Abstract:

Objective To investigate the changes and clinical significance of synovial fluid Asporin level in patients with temporomandibular joint disorders (TMD). Methods A total of 48 TMD patients who were treated in our hospital from January 2021 to December 2023 due to irritant pain and mouth opening limitation were randomly selected as the observation group, and 48 healthy volunteers were selected as the control group. The synovial fluid Asporin levels of the two groups were detected by enzyme-linked immunosorbent assay (ELISA). The difference of synovial fluid Asporin levels between the two groups was compared. The correlation between the synovial fluid Asporin levels and the clinical symptoms of TMD was analyzed. Results The synovial fluid Asporin level in the experimental group was significantly higher than that in the control group (P<0.05). The synovial fluid Asporin level was positively correlated with the pain degree of TMD patients (Rs=0.825, P<0.001), negatively correlated with the degree of mouth opening (Rs=-0.945, P<0.001). Conclusion The level of Asporin in synovial fluid of TMD patients was significantly increased. The level of Asporin in synovial fluid of TMD patients is correlated with the clinical symptoms of TMD, which provides a basis for the diagnosis and evaluation of TMD.

Key words: temporomandibular joint disorder, Asporin, immunosorbent assay (ELISA), biological marker